Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Recruiting · NCT06932081 · Observational (researchers observe without assigning treatment) · Lead sponsor: Leiden University Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
SGLT2 inhibitors
What this trial is about
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Congenital heart defect.
- Age ≥ 18 years.
- Initiated on treatment with an SGLT2i.
Exclusion criteria
- \- No consent for data collection.
Where it is running
11 locations listed across 3 US states.
- Johns Hopkins University - Baltimore, Maryland, United States
- Helen DeVos Children's Hospital - Grand Rapids, Michigan, United States
- Mount Sinai Fuster Heart Hospital - New York, New York, United States
- Amsterdam University Medical Center - Amsterdam, Netherlands
- University Hospital of Wales - Cardiff, United Kingdom
- Heart Center Duisburg (Evangelical Hospital Niederrhein) - Duisburg, Germany
- Golden Jubilee University National Hospital - Glasgow, United Kingdom
- Barts Heart Centre - London, United Kingdom
- Zan Mitrev Clinic - Skopje, North Macedonia
- University Medical Center Utrecht - Utrecht, Netherlands
- Leiden University Medical Center (LUMC) - Leiden, South Holland, Netherlands